Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung Diseases
- PMID: 27905854
- DOI: 10.1164/rccm.201606-1256LE
Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung Diseases
Comment in
-
Reply: Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung Diseases.Am J Respir Crit Care Med. 2016 Dec 1;194(11):1435-1436. doi: 10.1164/rccm.201607-1464LE. Am J Respir Crit Care Med. 2016. PMID: 27905855 Free PMC article. No abstract available.
Comment on
-
Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies.Am J Respir Crit Care Med. 2016 Dec 1;194(11):1392-1402. doi: 10.1164/rccm.201509-1865OC. Am J Respir Crit Care Med. 2016. PMID: 27310652 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
